Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. - Wikidata - awgldk - TriplyDB

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.

http://www.wikidata.org/entity/Q34535702

about

Erythropoietin or darbepoetin for patients with cancer Drug therapy for the management of cancer-related fatigue Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data Drug therapy for the management of cancer related fatigue Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data Erythropoietin or Darbepoetin for patients with cancer Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial.Erythropoiesis-stimulating agents in the management of cancer patients with anemia: a meta-analysis.Erythropoietin action in stress response, tissue maintenance and metabolism.Transfusions and patient burden in chemotherapy-induced anaemia in France The ESA APPRISE Oncology Program: A History of REMS Requirements, a Review of the Data, And an Approach to Compliance in the Hospital.Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.Overview of supportive care in patients receiving chemotherapy: antiemetics, pain management, anemia, and neutropenia.Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia.Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.Medical uses of erythropoietin.Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Darbepoetin alfa for the treatment of cancer-related anemia: an update.Optimising anaemia management with epoetin beta.Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.The burden of anaemia in patients with cancer.Strategies to optimize the use of erythropoietin and iron therapy in oncology patients.Management of cancer anemia.European Myeloma Network guidelines for the management of multiple myeloma-related complications.Management of cancer-related fatigue.Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.Trends in Anemia Management in Hemodialysis Patients with Cancer The development of erythropoietic agents in oncology.Anaemia of cancer: impact on patient fatigue and long-term outcome.

P2860

Q24202335-A0304383-1DC9-4032-B69E-191E16204AFB Q24234267-D1C45F15-839D-4D24-B9B9-39B7455FAB5F Q24240202-999C8D65-7863-4780-8E03-C588A630140A Q24242050-6258106F-2D68-4655-9BEC-C1C7D89867D8 Q24242864-707233B4-93A1-45D2-8B3A-966FF997F122 Q24245464-CFD598CE-3057-47C7-8B1B-E7607E8F6C39 Q30803363-FA569C78-A8D0-43FB-95F2-BA9748EE2F35 Q30964688-A9ECEBB0-7C9C-493F-BAD6-46D91F09CA9E Q33243661-9C6D43AE-ED4E-4CAD-BA0B-6698559AB3B9 Q33499897-9FB82E5B-341B-438B-9620-2F568D3AC81E Q33630871-805921ED-87BE-481F-9F03-78409CB30E6D Q33727356-6D34A771-582D-4342-9009-FA0FC6524B6D Q33827405-3629B3AC-48DE-46FD-B5C4-446E43E7FC6D Q33907747-FCF4E26E-68DB-4960-88CE-AEDC0B21D8F6 Q33937375-C6C84D92-CD70-446B-BB97-8823934F24A1 Q34022950-82DF3EE5-69AD-41D4-A5B6-5608432FDE5E Q34100489-ADE54263-A560-4944-A353-E9168175A70F Q34554073-8101BBEF-1C24-43EA-9F3D-192D45B9C2F0 Q34635638-0A338BBE-188A-4FCD-8FC6-46E542450ECE Q34961213-9689541D-09AB-41D5-AE6C-F92F379E4F9B Q35104268-A29423D5-967C-4D1A-9AA1-B86C0C5AF428 Q35166812-33C92DDB-6E2E-4831-865E-11D1B22F4BDE Q35217404-7E3B8A22-F7F0-4D62-BEDA-ECC984FC5EEF Q35583842-59859EA0-9FBB-427F-9E0D-A79745C26501 Q35620681-13937887-C082-4296-AF4F-28BB5167BEDA Q35696941-62A8B7BF-864A-4B4D-9484-4F4837C51BFB Q35812964-D55B2DE9-6237-4D7A-B168-3312F322EBE2 Q35858979-27E9215A-D1AF-45A9-903F-FF370F92EFBC Q35918431-85521E02-42EA-4380-A405-44A8A5E3C66E Q35919225-47C5C420-6FEB-4235-86D4-7F655D8C8C7B Q35919230-33C4025E-5C0D-4B01-968C-9D35BF782DF5 Q35920738-F8E778A6-682B-4E0D-AFAC-E0312F39071C Q35976513-C31553E8-CA64-4FB6-B416-C81A06CEF8F0 Q36028737-51DD795E-7383-4621-A2D8-9B47BA5C42C2 Q36115636-01E71F41-5334-419D-BCFA-89CDF3745BDF Q36156911-7A2FCE04-F769-4EB9-97C4-F47C645BD146 Q36193223-CEB079E2-8FF5-44A6-95CE-E638281B80DC Q36200205-5EECD5F9-4DEF-4BCE-9538-F3E5E9AC21E4 Q36219651-240453C2-C120-4FA8-B379-0B3761C8BCAA Q36294781-8D6CBECC-B984-4BA3-B685-3BA05C005DC6

P2860

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study.

http://www.wikidata.org/entity/Q34535702

description

2003 nî lūn-bûn

@nan

2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@ast

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@en

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@nl

type

label

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@ast

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@en

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@nl

prefLabel

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@ast

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@en

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@nl

P1433

Q34535702-DFCAAFFA-8B81-4498-9E42-5D220E7FDC9F

P1476

Q34535702-A3DF0C23-63E8-40F1-8524-0953E93E1764

P2093

Q34535702-12982C89-7937-46F4-BA24-2F6977E6351B

Q34535702-173D00C8-89CD-479B-B971-BEE1073A47E8

Q34535702-283BB05C-59AC-4EB1-AFE3-A8AB6DA8E680

Q34535702-4CCC1AF8-2E57-4988-9CA3-A2B546427E61

Q34535702-68E5FC9A-C793-4415-9F9A-45158832A297

Q34535702-8E2BF002-D00F-4C97-98DF-391780122D47

Q34535702-A502FB18-F128-4109-8911-046F01F212AF

Q34535702-BC76F59B-A612-4304-ABD2-8FD772564A30

Q34535702-CA31A2CD-97C7-47B9-A094-621D931DB9D4

Q34535702-CEEB4BAB-4B10-42B6-97E6-F40E6500CCF7

P2860

Q34535702-001293D4-FEFA-490D-8D2B-4EF483DC674E

Q34535702-188D0329-3906-4C45-BE8B-2E4DE08EA7C0

Q34535702-2BC0DA09-F258-48EF-B312-49579D0D354F

Q34535702-3D3C583B-FC01-404B-9F4F-3CF950CA8F77

Q34535702-3D91743B-BF6F-466F-9F07-27567062AAA1

Q34535702-4FA90BB8-FF4C-41E7-841C-B7229520DC11

Q34535702-B0CA47A1-7A6B-4CDB-9ABC-82B9F3C167AC

Q34535702-DDBB3D64-B188-497B-B5F7-9ABFD6063759

Q34535702-EF5B5C64-285A-4FEF-8713-5DB9103E0FBF

P304

Q34535702-7A1B6AE6-230D-48CA-A634-7F7E538B73EB

P31

Q34535702-40E2FF9E-9016-49C1-A898-E1F55F962141

P356

Q34535702-F692FAF7-B569-45F3-8740-C91FBBA11EEA

P407

Q34535702-D305B3CA-A528-46A2-B65D-6D798148E13F

P433

Q34535702-7809DD69-53D2-4115-AD3F-62BB97AF6740

P478

Q34535702-87DB1463-C210-439A-AAFE-DA3002115841

P50

Q34535702-F1531565-793B-417B-8C85-20C0E273CB3F

P577

Q34535702-F234C41E-BD57-4EF0-A0A5-84BB263CAED8

P5875

Q34535702-25984649-C930-41CE-A1A1-CF9AECB2D1FD

P698

Q34535702-26D6BA16-C2F1-4D2F-A634-9534C5FD9DED

P921

Q34535702-688AE141-5D41-488C-93A9-A353DAB694BC

Q34535702-9DA98728-64D5-45AE-946C-6780ABC1DFC7

Q34535702-B58221AB-99B8-48FA-B687-59A719AC3C8F

P356

J.1365-2141.2003.04448.X

P1433

British Journal of Haematology

P1476

Efficacy and safety of darbepo ...... ind, placebo-controlled study.

@en

P2093

Albert Altés

http://www.w3.org/2001/XMLSchema#string

Andrew Belch

http://www.w3.org/2001/XMLSchema#string

Darbepoetin Alfa 20000161 Study Group

http://www.w3.org/2001/XMLSchema#string

David Watson

http://www.w3.org/2001/XMLSchema#string

Eeva Juvonen

http://www.w3.org/2001/XMLSchema#string

Gregory Rossi

http://www.w3.org/2001/XMLSchema#string

James Matcham

http://www.w3.org/2001/XMLSchema#string

Jesus San Miguel

http://www.w3.org/2001/XMLSchema#string

Kerry Taylor

http://www.w3.org/2001/XMLSchema#string

Magnus Adriansson

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy-induced anemia in adults: incidence and treatment.

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy.

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.

Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma.

The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy.

Fatigue in cancer patients compared with fatigue in the general United States population.

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.

Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma.

P304

394-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2141.2003.04448.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Martinelli

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10646972

http://www.w3.org/2001/XMLSchema#string

P698

12877666

http://www.w3.org/2001/XMLSchema#string

P921

Darbepoetin alfa